CPHA Canvax

"The Novavax Nuvaxovid COVID-19 vaccine is the first COVID-19 recombinant protein subunit vaccine authorized in Canada. Novavax Nuvaxovid was authorized for use in adults ≥18 years of age by Health Canada on February 17, 2022." - NACI Recommendations on the use of Novavax Nuvaxovid COVID-19 vaccine 

Additional Authors: Robert G. Stirling, Kelsey Young, Matthew C. Tunis, Beate Sander, and Robyn Harrison


Related Resources


Implementation Tool



Vaccine Safety and Development,Vaccine Safety,Vaccine Safety,Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19,Program Planning and Delivery,Program Delivery and Evaluation,Clinics,Vaccine Management,Allocation and Distribution Vaccine Safety and Development
Vaccine Safety
Vaccine Safety
Monitoring and Surveillance
Outbreaks and Pandemics
Program Planning and Delivery
Program Delivery and Evaluation
Vaccine Management
Allocation and Distribution


Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.